ClinicalTrials.gg
CompletedNCT02931838Updated Nov 27, 2020Results posted

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

A Phase 2 interventional study of BMS-986165 and Placebo for BMS-986165 in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 76 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-11-27.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
8th of 26
268 · median 102
Started
2016
the only one that year
Phase 2
Only one
of the 26
Registered
1st of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 8th largest by enrollment, is the only one that started in 2016, is the only one in phase 2, and was the 1st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Male and female, ages 18 to 70 years
  • Diagnosis of plaque psoriasis for 6 months
  • Women of (WOCBP) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of for the duration of treatment plus 5 half-lives of the study drug plus 90 days.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Blood transfusion within 4 weeks of study drug administration
  • Inability to tolerate oral medication
  • Positive hepatitis-B () surface antigen
  • Positive hepatitis-C () antibody
  • Any history or risk for tuberculosis (TB)
  • Any major illness/condition or evidence of an unstable clinical condition
  • Chest X-ray findings suspicious of infection at screening
  • has received ustekinumab, secukinumab or ixekizumab within 6 months of first administration of study medication
  • Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first administration of study medication
  • Has received Rituximab within 6 months of first administration of study medication
  • Topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication
  • Any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
268 participants (actual)

Study arms

  • Experimental
    BMS-986165 Dose 1

    Specified dose of BMS-986165 on specified days.

    Drug: BMS-986165

  • Experimental
    BMS-986165 Dose 2

    Specified dose of BMS-986165 on specified days.

    Drug: BMS-986165

  • Experimental
    BMS-986165 Dose 3

    Specified dose of BMS-986165 on specified days.

    Drug: BMS-986165

  • Experimental
    BMS-986165 Dose 4

    Specified dose of BMS-986165 on specified days.

    Drug: BMS-986165

  • Experimental
    BMS-986165 Dose 5

    Specified dose of BMS-986165 on specified days.

    Drug: BMS-986165

  • Placebo comparator
    Placebo

    Specified dose of Placebo for BMS-986165 on specified days.

    Drug: Placebo for BMS-986165

Interventions

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)

    Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.

    Time frame: Day 1 to Day 85

  2. Number of Participants With Adverse Events

    The safety and tolerability of BMS-986195 as assessed by the number of subjects with adverse events (AEs); number of subjects with serious adverse events (SAEs); number of subjects with adverse events leading to discontinuation

    Time frame: Day 1 to day 115

Secondary outcomes

  1. Percentage of Participants on Day 85 With PASI-50, PASI-90, PASI-100.

    Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 90 and PASI 100 responses on Day 85. PASI 50 response: patients who achieved ≥ 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders. PASI 90 response: patients who achieved ≥ 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders. PASI 100 response: patients who achieved ≥ 100% improvement (reduction) in PASI score compared to baseline were defined as PASI 100 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.

    Time frame: Day 1 to Day 85

  2. Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).

    Percentage of participants achieving a clear (0) or almost clear (1) status on the Static Physician Global Assessment (sPGA) on Day 85. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling.

    Time frame: Day 1 to Day 85

  3. Change From Baseline in DLQI Scores on Day 85

    The DLQI is a participant reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 by a tick box: "not at all", "a little", "a lot", or "very much". The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment)

    Time frame: Day 1 to Day 85

  4. Change From Baseline in BSA on Day 85

    Measurement of psoriasis body surface area (BSA) involvement is estimated using the handprint method with the size of a patient's handprint representing \~1% of body surface area involved.The total BSA = 100% with breakdown by body region as follows: head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including axillae and groin = 30% (30 handprints), lower extremities including buttocks = 40% (40 handprints). A decrease from Baseline indicates improvement. Change from Baseline was calculated as Baseline score - Day 85 score; a positive change from Baseline therefore indicates improvement.

    Time frame: Day 1 to Day 85

  5. Trough Observed Plasma Concentration of BMS-986165 (Ctrough)

    Pharmacokinetics of BMS-986165 were derived from plasma concentration versus time data. Ctrough= Trough observed plasma concentration

    Time frame: Days 8, 15, 29, 57, 85

07

Results

Posted Nov 27, 2020
Limitations and caveats
The limitations of this phase 2 trial include its small sample size and short duration; these results warrant confirmation in a larger trial of longer duration

Participant flow

Participant flow — Overall Study
MilestonePlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QD
Started454444454544
Completed313436423942
Not completed14108362
Withdrew: Reason not provided by investigator101000
Withdrew: Poor/non-compliance001000
Withdrew: Lack of efficacy540001
Withdrew: Lost to follow-up101120
Withdrew: Subject request to discontinue treatment433010
Withdrew: Withdrawal by subject120100
Withdrew: Adverse event212131

Outcome measures

PrimaryThe Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)

Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.

Time frame:
Day 1 to Day 85
Reported as:
Number · Percentage
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)
PercentagePlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QD
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)6.7 (1.4 to 18.3)9.1 (2.5 to 21.7)38.6 (24.4 to 54.5)68.9 (53.4 to 81.8)66.7 (51.0 to 80.0)75.0 (59.7 to 86.8)
Statistical analysis
  • Placebo vs BMS-986165 3MG QOD · Chi-squared · p = 0.4873 (Nominal p-value)P-value is from the Fishers Exact if at least one cell count is \<5. Otherwise, p-value is from the Chi-Square test.
  • Placebo vs BMS-986165 3MG QD · Chi-squared · p = 0.0003 (Nominal p-value)P-value is from the Fishers Exact if at least one cell count is \<5. Otherwise, p-value is from the Chi-Square test.
  • Placebo vs BMS-986165 3MG BID · Chi-squared · p = <0.0001 (Nominal p-value)P-value is from the Fishers Exact if at least one cell count is \<5. Otherwise, p-value is from the Chi-Square test.
  • Placebo vs BMS-986165 6MG BID · Chi-squared · p = < 0.0001 (Nominal p-value)P-value is from the Fishers Exact if at least one cell count is \<5. Otherwise, p-value is from the Chi-Square test.
  • Placebo vs BMS-986165 12MG QD · Chi-squared · p = <0.0001 (Nominal p-value)P-value is from the Fishers Exact if at least one cell count is \<5. Otherwise, p-value is from the Chi-Square test.
SecondaryPercentage of Participants on Day 85 With PASI-50, PASI-90, PASI-100.

Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 90 and PASI 100 responses on Day 85. PASI 50 response: patients who achieved ≥ 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders. PASI 90 response: patients who achieved ≥ 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders. PASI 100 response: patients who achieved ≥ 100% improvement (reduction) in PASI score compared to baseline were defined as PASI 100 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.

Time frame:
Day 1 to Day 85
Reported as:
Number · Percentage
Percentage of Participants on Day 85 With PASI-50, PASI-90, PASI-100.
PercentagePlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QD
% of participants with PASI-50 at Day 8531.1 (18.2 to 46.6)43.2 (28.3 to 59.0)68.2 (52.4 to 81.4)91.1 (78.8 to 97.5)77.8 (62.9 to 88.8)88.6 (75.4 to 96.2)
% of participants with PASI-90 at Day 852.2 (0.1 to 11.8)6.8 (1.4 to 18.7)15.9 (6.6 to 30.1)44.4 (29.6 to 60.0)44.4 (29.6 to 60.0)43.2 (28.3 to 59.0)
% of participants with PASI-100 at Day 850 (0.0 to 7.9)2.3 (0.1 to 12.0)0 (0.0 to 8.0)8.9 (2.5 to 21.2)17.8 (8.0 to 32.1)25.0 (13.2 to 40.3)
SecondaryPercentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).

Percentage of participants achieving a clear (0) or almost clear (1) status on the Static Physician Global Assessment (sPGA) on Day 85. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling.

Time frame:
Day 1 to Day 85
Reported as:
Number · Percentage
Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).
PercentagePlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QD
Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).6.7 (1.4 to 18.3)20.5 (9.8 to 35.3)38.6 (24.4 to 54.5)75.6 (60.5 to 87.1)64.4 (48.8 to 78.1)75.0 (59.7 to 86.8)
SecondaryChange From Baseline in DLQI Scores on Day 85

The DLQI is a participant reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 by a tick box: "not at all", "a little", "a lot", or "very much". The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment)

Time frame:
Day 1 to Day 85
Reported as:
Mean · Score
Change From Baseline in DLQI Scores on Day 85
ScorePlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QD
Change From Baseline in DLQI Scores on Day 85-2.85 (-4.33 to -1.37)-3.76 (-5.15 to -2.38)-6.07 (-8.07 to -4.08)-9.67 (-11.42 to -7.93)-8.38 (-10.72 to -6.03)-10.16 (-12.27 to -8.06)
SecondaryChange From Baseline in BSA on Day 85

Measurement of psoriasis body surface area (BSA) involvement is estimated using the handprint method with the size of a patient's handprint representing \~1% of body surface area involved.The total BSA = 100% with breakdown by body region as follows: head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including axillae and groin = 30% (30 handprints), lower extremities including buttocks = 40% (40 handprints). A decrease from Baseline indicates improvement. Change from Baseline was calculated as Baseline score - Day 85 score; a positive change from Baseline therefore indicates improvement.

Time frame:
Day 1 to Day 85
Reported as:
Mean · Percentage
Change From Baseline in BSA on Day 85
PercentagePlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QD
Change From Baseline in BSA on Day 85-7.71 (-11.88 to -3.54)-5.50 (-8.17 to -2.83)-12.59 (-18.28 to -6.89)-18.60 (-23.69 to -13.52)-17.23 (-20.85 to -13.60)-15.16 (-18.64 to -11.69)
SecondaryTrough Observed Plasma Concentration of BMS-986165 (Ctrough)

Pharmacokinetics of BMS-986165 were derived from plasma concentration versus time data. Ctrough= Trough observed plasma concentration

Time frame:
Days 8, 15, 29, 57, 85
Reported as:
Mean · ng/mL
Trough Observed Plasma Concentration of BMS-986165 (Ctrough)
ng/mLBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QD
Trough Observed Plasma Concentration of BMS-986165 (Ctrough)2.024 ± 3.70613.145 ± 3.158814.819 ± 9.141026.257 ± 14.648317.824 ± 22.7536
PrimaryNumber of Participants With Adverse Events

The safety and tolerability of BMS-986195 as assessed by the number of subjects with adverse events (AEs); number of subjects with serious adverse events (SAEs); number of subjects with adverse events leading to discontinuation

Time frame:
Day 1 to day 115
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QD
No. of participants with SAEs111100
No. of participants with AEs242625293634
No. of participants discontinued due to AEs212131

Adverse events

Collected over 20 weeks (assessed up to November 16, 2017). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/45 (0%)1/45 (2.2%)13/45 (28.9%)
BMS-986165 3mg QOD0/44 (0%)1/44 (2.3%)14/44 (31.8%)
BMS-986165 3mg QD0/44 (0%)1/44 (2.3%)18/44 (40.9%)
BMS-986165 3mg BID0/45 (0%)1/45 (2.2%)15/45 (33.3%)
BMS-986165 6mg BID0/45 (0%)0/45 (0%)25/45 (55.6%)
BMS-986165 12mg QD0/44 (0%)0/44 (0%)19/44 (43.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboBMS-986165 3mg QODBMS-986165 3mg QDBMS-986165 3mg BIDBMS-986165 6mg BIDBMS-986165 12mg QD
Gastroenteritis rotavirusInfections and infestations0/451/440/440/450/450/44
Eye injuryInjury, poisoning and procedural complications0/450/441/440/450/450/44
Haemorrhagic anaemiaBlood and lymphatic system disorders1/450/440/440/450/450/44
Haemorrhoidal haemorrhageGastrointestinal disorders1/450/440/440/450/450/44
DizzinessNervous system disorders0/450/440/441/450/450/44
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboBMS-986165 3mg QODBMS-986165 3mg QDBMS-986165 3mg BIDBMS-986165 6mg BIDBMS-986165 12mg QD
Blood creatine phosphokinase increasedInvestigations1/450/441/440/454/457/44
NasopharyngitisInfections and infestations2/451/445/445/457/453/44
DiarrhoeaGastrointestinal disorders2/451/441/442/452/454/44
NauseaGastrointestinal disorders2/454/440/441/451/452/44
HeadacheNervous system disorders2/454/444/443/453/452/44
AcneSkin and subcutaneous tissue disorders0/451/440/441/452/454/44
Upper respiratory tract infectionInfections and infestations1/452/443/441/454/451/44
Blood immunoglobulin e increasedInvestigations1/453/442/440/452/453/44
PsoriasisSkin and subcutaneous tissue disorders2/451/443/442/450/450/44
Aphthous ulcerGastrointestinal disorders0/450/440/443/450/451/44

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QDTotal
Mean46.4 ± 11.9341.0 ± 11.845.0 ± 13.7745.6 ± 15.1042.8 ± 12.9046.6 ± 11.6244.6 ± 12.96
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QDTotal
Female881419101473
Male373630263530194
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBMS-986165 3MG QODBMS-986165 3MG QDBMS-986165 3MG BIDBMS-986165 6MG BIDBMS-986165 12MG QDTotal
American Indian or Alaska Native0100113
Asian56559636
Native Hawaiian or Other Pacific Islander0000000
Black or African American0101002
White403539393537225
More than one race0000000
Unknown or Not Reported0100001
08

Study locations

76 sites
  • University of California Irvine
    Irvine, California 92697, United States
  • University of California San Diego
    San Diego, California 92122, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Dermatologic Surgery Specialists, PC
    Macon, Georgia 31217, United States
  • PMG Research of Christie Clinic, LLC
    Champaign, Illinois 61820, United States
  • NorthShore University Health System
    Skokie, Illinois 60077, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
  • Piedmont Plastic Surgery & Dermatology - Charlotte/Blakeney Location
    Charlotte, North Carolina 28277, United States
  • PMG Research of Rocky Mount, LLC
    Rocky Mount, North Carolina 27804, United States
  • PMG Research of Wilmington, PLC
    Wilmington, North Carolina 28401, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Rivergate Dermatology Clinical Research Center, Pllc
    Goodlettsville, Tennessee 37072, United States
  • Local Institution
    Knoxville, Tennessee 37920, United States
  • Austin Dermatology Associates
    Austin, Texas 78705, United States
  • Local Institution
    Kogarah, New South Wales 2217, Australia
  • Local Institution
    Wolloongabba, Queensland 4102, Australia
  • Local Institution
    Melbourne, Victoria 3053, Australia
  • Local Institution
    Nedlands, Western Australia 6009, Australia
  • Local Institution
    Calgary, Alberta T2G 1B1, Canada
  • Local Institution
    Edmonton, Alberta T5K 1X3, Canada
  • Local Institution
    Vancouver, British Columbia V5Z 4E8, Canada
  • Local Institution
    Hamilton, Ontario L8N 1Y2, Canada
  • Local Institution
    Markham, Ontario L3P 1X2, Canada
  • Local Institution
    Mississauga, Ontario L5H 1G9, Canada
  • Local Institution
    Peterborough, Ontario K9J 5K2, Canada
  • Local Institution
    Toronto, Ontario M4W 2N2, Canada
  • Local Institution
    Waterloo, Ontario N2J 1C4, Canada
  • Local Institution
    Windsor, Ontario N8W 1E6, Canada
  • Local Institution
    Montreal, Quebec H3H 1V4, Canada
  • Local Institution
    Dresden, 01097, Germany
  • Local Institution
    Gera, 07548, Germany
  • Local Institution
    Hamburg, 20253, Germany
  • Local Institution
    Hamburg, 20354, Germany
  • Local Institution
    Kiel, 24103, Germany
  • Local Institution
    Kiel, 24105, Germany
  • Local Institution
    Luebeck, 23538, Germany
  • Local Institution
    Mahlow, 15831, Germany
  • Local Institution
    Mainz, 55131, Germany
  • Local Institution
    Schwerin, 19055, Germany
  • Local Institution
    Stuttgart, 70178, Germany
  • Local Institution
    Nagoya-shi, Aichi 4678602, Japan
  • Local Institution
    Fukuoka City, Fukuoka 814-0180, Japan
  • Local Institution
    Sapporo, Hokkaido 060-0063, Japan
  • Local Institution
    Kobe, Hyogo 6500017, Japan
  • Local Institution
    Kamigyo-ku, Kyoto 602-8566, Japan
  • Local Institution
    Shimotsuke-shi, Tochigi 3290498, Japan
  • Local Institution
    Minato-ku, Tokyo 105-8471, Japan
  • Local Institution
    Shinagawa-Ku, Tokyo 141-8625, Japan
  • Local Institution
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Local Institution
    Skinjuku-ku, Tokyo 1690073, Japan
  • Local Institution
    Kumamoto, 8608556, Japan
  • Local Institution
    Osaka, 5500012, Japan
  • Local Institution
    Tokyo, 1738606, Japan
  • Local Institution
    Daugavpils, LV-5404, Latvia
  • Local Institution
    Riga, LV-1001, Latvia
  • Local Institution
    Riga, LV-1003, Latvia
  • Local Institution
    Riga, LV-1011, Latvia
  • Local Institution
    Riga, LV-1013, Latvia
  • Local Institution
    Ventspils, LV3601, Latvia
  • Local Institution
    Zapopan, Jalisco 45030, Mexico
  • Local Institution
    Monterey, Nuevo LEON 64460, Mexico
  • Local Institution
    Krakow, 31-011, Poland
  • Local Institution
    Lodz, 90-436, Poland
  • Local Institution
    Lublin, 20-080, Poland
  • Local Institution
    Osielsko, 86-031, Poland
  • Local Institution
    Siedlce, 08 - 110, Poland
  • Local Institution
    Skierniewice, 96-100, Poland
  • Local Institution
    Warszawa, 00-660, Poland
  • Local Institution
    Warszawa, 01-142, Poland
  • Local Institution
    Warszawa, 01-817, Poland
  • Local Institution
    Warszawa, 02-758, Poland
  • Local Institution
    Warszawa, 02-777, Poland
  • Local Institution
    Wroc?aw, 51-318, Poland
  • Local Institution
    Wroclaw, 50368, Poland
09

References and documents

Publications

  • Thaci D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13. PubMed 35025062 ↗
  • Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 Jun;149(6):2010-2020.e8. doi: 10.1016/j.jaci.2021.11.001. Epub 2021 Nov 10. PubMed 34767869 ↗
  • Papp K, Gordon K, Thaci D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018 Oct 4;379(14):1313-1321. doi: 10.1056/NEJMoa1806382. Epub 2018 Sep 11. PubMed 30205746 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Nov 2017, 12 months.

Results were first posted in Nov 2020, 3 years after primary completion. A results delay was requested in Nov 2018.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 12 months is close to that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2016
First posted
Oct 13, 2016
StartActual
Nov 15, 2016
Primary completionActual
Nov 16, 2017
CompletionActual
Nov 16, 2017
Results delay requested
Nov 15, 2018
Results first posted
Nov 27, 2020
Last update
Nov 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02931838
Responsible party
Sponsor
First posted
Oct 13, 2016
Start date
Nov 15, 2016
Primary completion
Nov 16, 2017
Completion
Nov 16, 2017
Results posted
Nov 27, 2020
Last update
Nov 27, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion